The stock of Pacific Biosciences of California Inc. (PACB) has seen a 2.70% increase in the past week, with a 15.97% gain in the past month, and a 34.76% flourish in the past quarter. The volatility ratio for the week is 5.84%, and the volatility levels for the past 30 days are at 6.06% for PACB. The simple moving average for the past 20 days is 6.64% for PACB’s stock, with a 38.46% simple moving average for the past 200 days.
Is It Worth Investing in Pacific Biosciences of California Inc. (NASDAQ: PACB) Right Now?
while the 36-month beta value is 1.65.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The average price point forecasted by analysts for Pacific Biosciences of California Inc. (PACB) is $13.80, which is $1.24 above the current market price. The public float for PACB is 206.29M, and currently, short sellers hold a 12.33% ratio of that floaft. The average trading volume of PACB on May 24, 2023 was 3.64M shares.
PACB) stock’s latest price update
The stock price of Pacific Biosciences of California Inc. (NASDAQ: PACB) has dropped by -3.83 compared to previous close of 13.06. Despite this, the company has seen a gain of 2.70% in its stock price over the last five trading days. Barron’s reported on 10/26/22 that Pacific Bio Pushes Back at Illumina With New No-Compromise Gene Readers
PACB Trading at 16.26% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.55% of loss for the given period.
Volatility was left at 6.06%, however, over the last 30 days, the volatility rate increased by 5.84%, as shares surge +23.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.87% upper at present.
During the last 5 trading sessions, PACB rose by +2.70%, which changed the moving average for the period of 200-days by +107.26% in comparison to the 20-day moving average, which settled at $11.90. In addition, Pacific Biosciences of California Inc. saw 53.55% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PACB starting from Farmer Michele, who sale 5,165 shares at the price of $12.59 back on May 18. After this action, Farmer Michele now owns 107,577 shares of Pacific Biosciences of California Inc., valued at $65,027 using the latest closing price.
Ericson William W., the Director of Pacific Biosciences of California Inc., sale 7,541 shares at $8.90 during a trade that took place back on Mar 15, which means that Ericson William W. is holding 18,795 shares at $67,115 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -237.58 for the present operating margin
- +38.08 for the gross margin
The net margin for Pacific Biosciences of California Inc. stands at -244.92. The total capital return value is set at -18.70, while invested capital returns managed to touch -19.40. Equity return is now at value -50.10, with -17.40 for asset returns.
Based on Pacific Biosciences of California Inc. (PACB), the company’s capital structure generated 168.59 points at debt to equity in total, while total debt to capital is 62.77. Total debt to assets is 53.70, with long-term debt to equity ratio resting at 166.68. Finally, the long-term debt to capital ratio is 62.06.
When we switch over and look at the enterprise to sales, we see a ratio of 25.67, with the company’s debt to enterprise value settled at 0.47. The receivables turnover for the company is 5.96 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.24.
In a nutshell, Pacific Biosciences of California Inc. (PACB) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.